Zhejiang AngLiKang PharmaceuticalLTD Past Earnings Performance
Past criteria checks 1/6
Zhejiang AngLiKang PharmaceuticalLTD's earnings have been declining at an average annual rate of -1.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 5.5% per year. Zhejiang AngLiKang PharmaceuticalLTD's return on equity is 8.3%, and it has net margins of 5%.
Key information
-1.9%
Earnings growth rate
-3.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 5.5% |
| Return on equity | 8.3% |
| Net Margin | 5.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Zhejiang AngLiKang PharmaceuticalLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,560 | 79 | 273 | 209 |
| 30 Jun 24 | 1,630 | 102 | 292 | 191 |
| 31 Mar 24 | 1,609 | 120 | 330 | 172 |
| 31 Dec 23 | 1,626 | 138 | 395 | 143 |
| 30 Sep 23 | 1,692 | 129 | 492 | 145 |
| 30 Jun 23 | 1,708 | 152 | 572 | 127 |
| 31 Mar 23 | 1,655 | 135 | 617 | 119 |
| 01 Jan 23 | 1,568 | 127 | 631 | 113 |
| 30 Sep 22 | 1,457 | 153 | 641 | 83 |
| 30 Jun 22 | 1,450 | 133 | 638 | 69 |
| 31 Mar 22 | 1,400 | 126 | 660 | 56 |
| 01 Jan 22 | 1,380 | 120 | 674 | 53 |
| 30 Sep 21 | 1,358 | 115 | 643 | 52 |
| 30 Jun 21 | 1,315 | 144 | 678 | 49 |
| 31 Mar 21 | 1,303 | 155 | 696 | 45 |
| 31 Dec 20 | 1,290 | 164 | 748 | 44 |
| 30 Sep 20 | 1,247 | 146 | 781 | 49 |
| 30 Jun 20 | 1,256 | 132 | 804 | 45 |
| 31 Mar 20 | 1,319 | 120 | 837 | 42 |
| 31 Dec 19 | 1,396 | 112 | 828 | 37 |
| 30 Sep 19 | 1,437 | 100 | 835 | 40 |
| 30 Jun 19 | 1,389 | 89 | 809 | 45 |
| 31 Mar 19 | 1,371 | 109 | 747 | 47 |
| 31 Dec 18 | 1,255 | 109 | 687 | 46 |
| 30 Sep 18 | 1,167 | 122 | 652 | 44 |
| 31 Dec 17 | 873 | 101 | 285 | 41 |
| 31 Dec 16 | 672 | 82 | 105 | 0 |
| 31 Dec 15 | 774 | 64 | 95 | 0 |
| 31 Dec 14 | 682 | 50 | 87 | 0 |
Quality Earnings: 002940 has high quality earnings.
Growing Profit Margin: 002940's current net profit margins (5%) are lower than last year (7.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002940's earnings have declined by 1.9% per year over the past 5 years.
Accelerating Growth: 002940's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002940 had negative earnings growth (-39.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 002940's Return on Equity (8.3%) is considered low.